eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
9.50
-0.05 (-0.52%)
May 19, 2026, 4:00 PM EDT - Market closed
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
80.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 66.16M |
| Champions Oncology | 57.95M |
| Gossamer Bio | 55.54M |
| ImmuCell | 29.93M |
| Atara Biotherapeutics | 23.14M |
| Alterity Therapeutics | 4.43M |
EXOZ News
- 5 days ago - eXoZymes Quarterly report: Q1 2026 - Filings
- 12 days ago - eXoZymes announces graduation from Shell GameChanger Accelerator - TheFly
- 12 days ago - eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - Accesswire
- 12 days ago - eXoZymes Slides: Investor presentation - Filings
- 5 weeks ago - eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - Accesswire
- 5 weeks ago - eXoZymes Slides: Investor presentation - Filings
- 6 weeks ago - eXoZymes Slides: Investor presentation - Filings
- 7 weeks ago - eXoZymes Earnings Call Transcript: Q4 2025 - Transcripts